{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:31:33Z","timestamp":1788985893512,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s11060-026-05712-2","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T14:57:10Z","timestamp":1784818630000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-term outcomes in IDH-wildtype (IDH-wt) gliomas with historical WHO grade 2 and 3 histology"],"prefix":"10.1007","volume":"179","author":[{"given":"Patrick P.","family":"Carriere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ory","family":"Haisraely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Aaroe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayode","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darien","family":"Colson-Fearon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"McArthur","family":"Bolden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"Beckham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"De","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subha","family":"Perni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin C.","family":"Tom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"McGovern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary F.","family":"McAleer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol","family":"Ghia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Grosshans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leomar","family":"Ballester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshua","family":"Esquenazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Kamiya-Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2901-7477","authenticated-orcid":false,"given":"Debra Nana","family":"Yeboa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"issue":"8","key":"5712_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"issue":"4","key":"5712_CR2","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00401-018-1908-x","volume":"136","author":"W Wick","year":"2018","unstructured":"Wick W, Blay JY, Mehta MP, Aldape K, Gilbert MR (2018) Molecular classification of diffuse gliomas: a new era in the WHO classification. Acta Neuropathol 136(4):539\u2013548. https:\/\/doi.org\/10.1007\/s00401-018-1908-x","journal-title":"Acta Neuropathol"},{"issue":"1","key":"5712_CR3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11060-025-05269-6","volume":"176","author":"DN Yeboa","year":"2025","unstructured":"Yeboa DN, Whitfield BT, Lin R, Ejezie CL, Swanson TA, Beckham TH, Wang C, De B, Perni S, Tom MC, Li J et al (2025) Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses: treatment intensification, margin reduction and epigenetic stratified outcomes with radiation therapy and chemotherapy. J Neurooncol 176(1):72. https:\/\/doi.org\/10.1007\/s11060-025-05269-6","journal-title":"J Neurooncol"},{"issue":"6","key":"5712_CR4","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S1470-2045(21)00071-9","volume":"22","author":"MJ van den Bent","year":"2021","unstructured":"van den Bent MJ, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA et al (2021) Adjuvant and concurrent temozolomide in 1p\/19q non-co-deleted anaplastic glioma (CATNON): a randomised, open-label, phase 3 study. Lancet Oncol 22(6):813\u2013823. https:\/\/doi.org\/10.1016\/S1470-2045(21)00071-9","journal-title":"Lancet Oncol"},{"issue":"2","key":"5712_CR5","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/neuonc\/noad158","volume":"26","author":"H Pinson","year":"2024","unstructured":"Pinson H, Silversmit G, Vanhauwaert D, Vanschoenbeek K, Okito JK, De Vleeschouwer S, Boterberg T, De Gendt C (2024) Epidemiology and survival of adult-type diffuse glioma in Belgium during the molecular era. Neuro Oncol 26(2):191\u2013202. https:\/\/doi.org\/10.1093\/neuonc\/noad158","journal-title":"Neuro Oncol"},{"issue":"1","key":"5712_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11060-022-03960-6","volume":"157","author":"A Ramos-Fresnedo","year":"2022","unstructured":"Ramos-Fresnedo A, Pullen MW, Perez-Vega C, Domingo RA, Akinduro OO, Almeida JP et al (2022) The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study. J Neurooncol 157(1):177\u2013185. https:\/\/doi.org\/10.1007\/s11060-022-03960-6","journal-title":"J Neurooncol"},{"issue":"14","key":"5712_CR7","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1200\/JCO.2015.61.2541","volume":"34","author":"W Wick","year":"2016","unstructured":"Wick W, Roth P, Hartmann C, Hau P, Nakamura M, Papendorf F, Weller J, Weller M (2016) Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma. J Clin Oncol 34(14):1614\u20131623. https:\/\/doi.org\/10.1200\/JCO.2015.61.2541","journal-title":"J Clin Oncol"},{"issue":"3","key":"5712_CR8","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1200\/JCO.2012.43.2229","volume":"31","author":"MJ van den Bent","year":"2013","unstructured":"van den Bent MJ, Brandes AA, Taphoorn MJB, Kros JM, Kouwenhoven MCM, Delattre JY et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31(3):344\u2013350. https:\/\/doi.org\/10.1200\/JCO.2012.43.2229","journal-title":"J Clin Oncol"},{"issue":"10","key":"5712_CR9","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"issue":"5","key":"5712_CR10","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459\u2013466. https:\/\/doi.org\/10.1016\/S1470-2045(09)70025-7","journal-title":"Lancet Oncol"},{"issue":"6","key":"5712_CR11","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S1470-2045(15)00070-0","volume":"16","author":"MJB Taphoorn","year":"2015","unstructured":"Taphoorn MJB, Henriksson R, Bottomley A, Cloughesy T, Wick W et al (2015) Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol 16(6):683\u2013691. https:\/\/doi.org\/10.1016\/S1470-2045(15)00070-0","journal-title":"Lancet Oncol"},{"issue":"8","key":"5712_CR12","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699\u2013708. https:\/\/doi.org\/10.1056\/NEJMoa1308573","journal-title":"N Engl J Med"},{"issue":"3","key":"5712_CR13","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC et al (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18(3):170\u2013186. https:\/\/doi.org\/10.1038\/s41571-020-00447-z","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"5712_CR14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699\u2013708. https:\/\/doi.org\/10.1056\/NEJMoa1308573","journal-title":"N Engl J Med"},{"issue":"1","key":"5712_CR15","doi-asserted-by":"publisher","first-page":"vdae228","DOI":"10.1093\/noajnl\/vdae228","volume":"7","author":"K Aldape","year":"2025","unstructured":"Aldape K, Capper D, von Deimling A, Giannini C, Gilbert MR, Hawkins C, Hench J, Jacques TS, Jones D, Louis DN, Mueller S, Orr BA, Nasrallah M, Pfister SM, Sahm F, Snuderl M, Solomon D, Varlet P, Wesseling P (2025) cIMPACT-NOW update 9: recommendations on utilization of genome-wide DNA methylation profiling for central nervous system tumor diagnostics. Neurooncol Adv 7(1):vdae228. https:\/\/doi.org\/10.1093\/noajnl\/vdae228","journal-title":"Neurooncol Adv"},{"issue":"1","key":"5712_CR16","doi-asserted-by":"publisher","first-page":"e70035","DOI":"10.1111\/bpa.70035","volume":"36","author":"P Wesseling","year":"2026","unstructured":"Wesseling P, Capper D, Reifenberger G, Sarkar C, Hawkins C, Perry A, Kleinschmidt-DeMasters B, Komori T, Paulus W, Santosh V, van den Bent M, Weller M, Pfister SM, Tabori U, Figarella-Branger D, Orr BA, Louis DN (2026) cIMPACT-NOW update 11: Proposal on adaptation of diagnostic criteria for IDH- and H3-wildtype diffuse high-grade gliomas and for posterior fossa ependymal tumors. Brain Pathol 36(1):e70035. https:\/\/doi.org\/10.1111\/bpa.70035","journal-title":"Brain Pathol"},{"issue":"3","key":"5712_CR17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s00415-025-12923-6","volume":"272","author":"MJ Mair","year":"2025","unstructured":"Mair MJ, Leibetseder A, Heller G, Tomasich E, M\u00fcller L, Busse I, W\u00f6hrer A, Kiesel B, Widhalm G, Eckert F, Weis S, Pichler J, Preusser M, Berghoff AS (2025) Clinical characteristics, molecular reclassification trajectories and DNA methylation patterns of long- and short-term survivors of WHO grade II and III glioma. J Neurol 272(3):210. https:\/\/doi.org\/10.1007\/s00415-025-12923-6","journal-title":"J Neurol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05712-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05712-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05712-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:27:04Z","timestamp":1788247624000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05712-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["5712"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05712-2","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"23 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (IRB) of The University of Texas MD Anderson Cancer Center (IRB approval number #2023\u2009\u2212\u20090812; approved October 24, 2023). Given the retrospective nature of the study, the requirement for individual informed consent was waived by the IRB.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was a retrospective review of existing medical records. The requirement for individual informed consent to participate was waived by the Institutional Review Board of The University of Texas MD Anderson Cancer Center in accordance with applicable regulations.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"12"}}